- Class: Multi-targeted tyrosine kinase inhibitor (TKI)
- Targets: VEGFR, MET, AXL, RET, KIT, and others
- Indications:
- Cabometyx®: Advanced renal cell carcinoma (RCC), hepatocellular carcinoma (HCC), medullary thyroid cancer (MTC)
- Cometriq®: Progressive, metastatic MTC
- Dose (RCC): 60 mg orally once daily (Cabometyx®)
- Key Toxicities:
- Hypertension, hand-foot syndrome, diarrhea
- Fatigue, mucosal inflammation, proteinuria
- Risk of hemorrhage, GI perforation, thromboembolic events
- Monitoring:
- BP, LFTs, renal function, electrolytes, proteinuria
- Drug interactions (CYP3A4 substrate)
Synonyms
Cabometyx, Cometriq